Lexeo Therapeutics, Inc. (LXEO) Balance Sheet

NASDAQ: LXEOAssets, liabilities, debt and equity over 6 years.

LXEO balance sheet, 2025

December 31, 2025 · U.S. dollars

$268.7M assets = $22.0M liabilities + $246.7M equity

What it owns$268.7MCash & ST investments: $181.8M (67.6%)Cash & ST investments$181.8M · 68%Other current: $6.6M (2.5%)PP&E: $8.9M (3.3%)LT investments: $68.2M (25.4%)LT investments$68.2M · 25%Other non-current: $3.2M (1.2%)=How it is financed$268.7MCurrent liabilities: $16.8M (6.3%)Current liabilities $16.8MOther LT liabilities: $5.2M (1.9%)Shareholders’ equity: $246.7M (91.8%)Shareholders’ equity$246.7M · 92%

Both columns are drawn to the same scale: what LXEO owns equals what it owes plus shareholders’ equity. Hover a block for its value.

LXEO financial health

Debt / equity0.03
Low leverage · $0.03 of debt for each $1 of equity
Equity / assets91.8%
Equity-funded · of assets funded by shareholders
Cash / debt2,304.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

LXEO balance sheet trends, 2020–2025

Lexeo Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$29.4M2020$268.7M2025+55.7%/yr
Total liabilities$34.9M2020$22.0M2025−8.8%/yr
Shareholders’ equity−$5.5M2020$246.7M2025—
Cash & short-term investments$29.4M2020$181.8M2025+44.0%/yr
Total debt$3.0M2020$7.9M2025+21.2%/yr
Net cash (debt)$26.4M2020$173.9M2025+$147.5M
Working capital$28.7M2020$171.6M2025+$142.9M
Book value per share−$0.222020$4.602025—
Debt / equity0.1020230.032025−0.07
Shares outstanding25.2M202053.6M2025+16.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

LXEO assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

LXEO liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

LXEO debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

LXEO balance sheet

Lexeo Therapeutics, Inc. annual balance sheet
202520242023202220212020
Assets
Cash & short-term investments$181.8M$121.5M$121.5M$77.3M$135.9M$29.4M
Cash & equivalents$63.0M$35.0M$121.5M$77.3M$135.9M$29.4M
Short-term investments$118.8M$86.5M$0———
Receivables$0$0$0$0$0$0
Inventory$0$0$0$0$0$0
Other current assets$6.6M$4.6M$2.8M$2.7M$824,000$33,572
Total current assets$188.4M$126.1M$124.3M$80.0M$136.7M$29.4M
Property, plant & equipment (net)$8.9M$10.6M$12.3M$13.8M$174,000$0
Goodwill & intangible assets$0$0$0$0$0$0
Long-term investments$68.2M$7.0M$0$0$0$0
Other non-current assets$3.2M$3.3M$3.3M$3.3M$2,000$2,500
Total assets$268.7M$146.9M$139.8M$97.1M$136.9M$29.4M
Liabilities
Accounts payable$4.9M$6.4M$3.8M$2.7M$3.1M$44,319
Short-term debt$2.7M$2.7M$2.6M$2.8M$4.3M$513,019
Deferred revenue——$10.7M$8.6M$46,000$140,384
Total current liabilities$16.8M$22.8M$17.2M$14.3M$7.4M$697,722
Long-term debt$0$0$0$0$0$0
Lease obligations$7.9M$9.9M$11.6M$13.5M$0—
Other long-term liabilities$5.2M$7.3M$9.0M$195.7M$185.0M$34.2M
Total liabilities$22.0M$30.1M$26.3M$210.0M$192.5M$34.9M
Shareholders' equity
Common stock & paid-in capital$7,000$3,000$3,000$2,000$1,675$1,604
Retained earnings (deficit)−$380.1M−$280.2M−$181.8M−$115.4M−$56.2M−$5.5M
Accumulated other comprehensive income$188,000−$103,000−$139.8M−$185.0M−$185.0M−$31.2M
Total shareholders' equity$246.7M$116.8M$113.5M−$113.0M−$55.6M−$5.5M
Key figures
Total debt$7.9M$9.9M$11.6M$13.5M$4.3M$3.0M
Net cash (debt)$173.9M$111.6M$109.8M$63.9M$131.5M$26.4M
Working capital$171.6M$103.3M$107.1M$65.7M$129.2M$28.7M
Tangible book value$246.7M$116.8M$113.5M−$113.0M−$55.6M−$5.5M
Book value per share$4.60$3.68$4.26−$4.49−$2.21−$0.22
Shares outstanding53.6M31.8M26.6M25.2M25.2M25.2M
Current ratio11.215.527.215.5818.3542.15
Quick ratio10.815.327.055.3918.2442.10
Debt / equity0.030.080.10———
Equity / assets91.8%79.5%81.2%−116.4%−40.6%−18.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.

LXEO financial position

At the end of fiscal 2025 (December 31, 2025), Lexeo Therapeutics had total assets of $268.7 million (up 82.9% from a year earlier), total liabilities of $22.0 million and shareholders' equity of $246.7 million. It held $181.8 million in cash and short-term investments against $7.9 million of debt, a net cash position of $173.9 million. Its current ratio was 11.21. In the latest quarter (ended June 30, 2026) total assets were $254.9 million and equity $235.1 million.

Related: LXEO income statement, LXEO cash flow statement, LXEO key metrics. See the LXEO stock overview for the latest quote and news.

LXEO balance sheet FAQ

What are Lexeo Therapeutics's total assets?

Lexeo Therapeutics reported total assets of $268.7 million at the end of fiscal 2025 (December 31, 2025), compared with $146.9 million a year earlier.

How much debt does Lexeo Therapeutics have?

Lexeo Therapeutics had $7.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.03.

How much cash does Lexeo Therapeutics have?

Lexeo Therapeutics held $181.8 million in cash and short-term investments at the end of fiscal 2025; with $7.9 million of debt that is net cash of $173.9 million.

What is Lexeo Therapeutics's book value?

Lexeo Therapeutics's shareholders' equity (book value) was $246.7 million at the end of fiscal 2025, or $4.60 per share.

What is Lexeo Therapeutics's current ratio?

Lexeo Therapeutics had current assets of $188.4 million and current liabilities of $16.8 million, a current ratio of 11.21 (it can cover its short-term obligations).

Biotechnology: balance sheet